Peptides Weight LossMetabolic Human clinical data

Survodutide

Survodu · BI 456906

6 days

Half-life

0.72–9.6 mg

Typical dose

Chronic (trials ran 46+ weeks)

Cycle length

Investigational dual GLP-1/glucagon receptor agonist for obesity and MASH; weekly injection.

Key takeaways

Investigational dual GLP-1/glucagon agonist in phase 3 for obesity and MASH; not approved anywhere yet.
Phase 2 obesity trial showed dose-dependent weight loss up to about 19% over 46 weeks.
Roughly 6-day estimated half-life; once-weekly injection titrated up to 6 mg in phase 2 trials.
GI side effects (nausea, vomiting, diarrhea) were the most common trial adverse events.

🚧 Expanded guide coming soon. This compound has PK data and a source — a full overview, mechanism, and dosing guide is pending editorial review.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case	Dose	Route	Frequency	Duration
Obesity (phase 2 trial)	0.6–6.0 mg, titrated every 2 weeks	SubQ	Once weekly	46 weeks

Pharmacokinetic summary

Model tier: Simple (t½ + F, Tmax estimated)
Half-life: 6 days
Bioavailability: 80%
Typical dose: 0.72–9.6 mg

Frequently asked questions

Is survodutide approved?

No. It's an investigational drug in phase 3 trials (the SYNCHRONIZE program) for obesity and MASH. Everything known about dosing comes from trial protocols, not an approved label.

How is survodutide different from tirzepatide or semaglutide?

It adds glucagon receptor activity to GLP-1, where semaglutide is GLP-1-only and tirzepatide is GIP/GLP-1. The glucagon arm is meant to raise energy expenditure and target liver fat, which is why MASH is a lead indication.

What did the MASH trial show?

In the phase 2 NEJM trial, significantly more participants on survodutide achieved MASH improvement without worsening fibrosis than on placebo, based on biopsy data over 48 weeks. Promising, but phase 3 confirmation is still pending.

References

Estimated (limited public PK) — Dual GLP-1/glucagon agonist; ~weekly half-life.
le Roux et al., Lancet Diabetes Endocrinol 2024 — phase 2 obesity trial — Randomized dose-finding trial: dose-dependent weight loss up to about 19% at 46 weeks.
Sanyal et al., NEJM 2024 — phase 2 MASH trial — Survodutide improved MASH without worsening fibrosis versus placebo over 48 weeks.

Comments

Loading comments…